ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

BACKGROUND: Durva is a human IgG1 mAb against PD-L1. Blockade of PD-1/PD-L1 has shown benefit among solid tumors; data implicate PD-1/PD-L1 signaling as a significant contributor to immunosuppression in GBM. BEV is an approved angiogenesis inhibitor for recurrent GBM; angiogenesis inhibition may pro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Reardon, David, Kaley, Thomas, Dietrich, Jorg, Clarke, Jennifer, Dunn, Gavin, Lim, Michael, Cloughesy, Tim, Gan, Hui, Park, Andrew, Schwarzenberger, Paul, Ricciardi, Toni, Macri, Mary, Ryan, Aileen, Venhaus, Ralph
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216149/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.033
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars